| [1] | Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull World Health Organ. 1964;31:273–94. pmid:14253244
|
| [2] | Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. American review of tuberculosis. 1952;65(5):523–46. pmid:14924175
|
| [3] | Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970;283(12):616–21. pmid:4988918 doi: 10.1056/nejm197009172831202
|
| [4] | Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB—Final Study Outcomes. N Engl J Med. 2015;373(3):290–1. doi: 10.1056/NEJMc1500286. pmid:26176401
|
| [5] | Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis. 1999;3(1):1–3. pmid:10094162
|
| [6] | Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345(8964):1545–8. pmid:7677849 doi: 10.1016/s0140-6736(95)91090-5
|
| [7] | World Health Organization Global Tuberculosis Programme. Framework for effective tuberculosis control. WHO/TB/94.179. Geneva; WHO, 1994.
|
| [8] | Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328(8):521–6. pmid:8381207 doi: 10.1056/nejm199302253280801
|
| [9] | Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014;17:19045. doi: 10.7448/IAS.17.1.19045. pmid:25516092
|
| [10] | Annas GJ. Control of tuberculosis—the law and the public's health. N Engl J Med. 1993;328(8):585–8. pmid:8426636 doi: 10.1056/nejm199302253280825
|
| [11] | Sagbakken M, Frich JC, Bjune GA, Porter JD. Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC Med Ethics. 2013;14:25. doi: 10.1186/1472-6939-14-25. pmid:23819555
|
| [12] | Daftary A, Padayatchi N, O'Donnell M. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health. 2014;9(9):1107–16. doi: 10.1080/17441692.2014.934266. pmid:25035943
|
| [13] | Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–74. pmid:21406048 doi: 10.2174/187152611795589663
|
| [14] | van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8. doi: 10.1111/j.1365-3156.2011.02755.x. pmid:21375681
|
| [15] | Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330(17):1179–84. pmid:8139628 doi: 10.1056/nejm199404283301702
|
| [16] | Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 1999;3(1):4–11. pmid:10094163
|
| [17] | Volmink J, Garner P. Directly observed therapy for treating tuberculosis. The Cochrane database of systematic reviews. 2007;(4):CD003343. pmid:17943789 doi: 10.1002/14651858.cd003343.pub2
|
| [18] | Pope DS, Chaisson RE. TB treatment: as simple as DOT? Int J Tuberc Lung Dis. 2003;7(7):611–5. pmid:12870680
|
| [19] | Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204(12):1951–9. doi: 10.1093/infdis/jir658. pmid:22021624
|
| [20] | Ankomah P, Levin BR. Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012;8(1):e1002487. doi: 10.1371/journal.ppat.1002487. pmid:22253599
|
| [21] | Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32. pmid:8426619 doi: 10.1056/nejm199302253280802
|
| [22] | Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197 Suppl 3:S272–8. doi: 10.1086/533415. pmid:18447613
|
| [23] | Petersen ML, LeDell E, Schwab J, Sarovar V, Gross R, Reynolds N, et al. Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr. 2015;69(1):109–18. doi: 10.1097/QAI.0000000000000548. pmid:25942462
|
| [24] | Curry FJ. Encounters in training clinic support staff. Chest. 1975;68(3 Suppl):462–5. pmid:1157565 doi: 10.1378/chest.68.3.462
|
